Definium Therapeutics is a healthcare company focused on developing innovative therapies for cancer treatment. Its core products include targeted therapies and immunotherapies aimed at specific cancer types. The company operates primarily in the biotechnology segment, with its main revenue sources stemming from research collaborations, grants, and potential future product sales. Definium is engaged in clinical trials to advance its pipeline of drug candidates.
The investment profile of Definium Therapeutics is more aligned with growth investors, given its focus on developing new therapies and the potential for significant future returns. However, the high risk associated with its current financial performance and lack of revenue may deter conservative investors. The stock may appeal to those with a longer investment horizon who are willing to accept volatility in pursuit of growth opportunities.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-11 05:18 | Sell | Hold | Weak fundamentals and high volatility raise concerns. |
| 2026-06-01 02:36 | Hold | Sell | High volatility; fundamentals show significant weakness. |
| 2026-05-20 02:41 | Sell | Hold | Weak fundamentals and negative momentum raise significant concerns. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-05-08 11:05 | Piper Sandler | Target Lowered | 49 → 48 | 23.2 |
| 2026-04-23 12:57 | Oppenheimer | Target Raised | 25 → 40 | 22.925 |
| 2026-04-16 20:22 | Stifel Nicolaus | Update | — → 30 | 22.46 |
